Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, compared with placebo...

concluding it wasn't sufficiently effective to be a competitive product. Obicetrapib (TA-8995, AMG-899): Phase II results were reported in 2015 and Phase...

protein (CETP) inhibitors include the agents torcetrapib, anacetrapib and obicetrapib. They block transfer of cholesterol from "good" HDL particles to "bad"...